Techulon is leading the next generation of disease treatment through development of safe and effective treatments for drug resistant infections. The company uses a proven method to defeat bacteria at the genomic level. Unlike current antibiotics on the market, the drugs that are derived from Techulon’s approach are potent and not susceptible to resistance.Techulon's enabling technology is a robust platform that allows for delivery of nucleic acids for a variety of therapeutic applications. The company has recently been awarded a $1.9M contract from DARPA to advance its antimicrobial platform to fight both Gram-negative as well as Gram-positive bacteria. Using a novel informatics approach, the company has identified new gene targets and is developing antimicrobial therapeutics for broad applications.